Contact us | Levi & Korsinsky, LLP | Securities Class Action Attorneys

55

Days Left

SANA

Sana Biotechnology, Inc.

Deadline

May 20 2025

Class Period

3/17/23 - 11/4/24

Allegations

(i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (iv) accordingly, defendants overstated Sana’s financial capacity to maintain its current operations and advance its existing product candidates; and (v) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

3/17/23 - 11/4/24

Deadline

May 20 2025

Learn More

55

Days Left

PPTA

Perpetua Resources Corp.

Deadline

May 20 2025

Class Period

4/17/24 - 2/13/25

Allegations

According to the complaint, defendants provided investors with material information concerning Perpetua’s expected initial capital expenditure for the Stibnite Gold Project. Defendants’ statements included, among other things, minimization of the impact of inflation and other potential sources for increased capital expenditure costs for the project. On February 13, 2025, Perpetua published an updated cash flow model for the Stibnite Gold Project, unveiling additional capital expenses of $952 million, a more than 75% increase from the original figures presented to investors and well beyond the suggested 10-20% increase contemplated by defendants. The Company attributed these increased costs on inflation, indirect costs, higher mining costs, and direct decisions defendants made with respect to the project, including the choice to change the design of the electrical poles from timber to steel and the decision to “buy-and-build instead of lease the oxygen plant.” Following this news, the price of Perpetua’s common stock declined dramatically. From a closing market price of $11.97 per share on February 13, 2025, Perpetua’s stock price fell to $9.29 per share on February 14, 2025, a decline of about 22.39% in the span of just a single day.

Class Period

4/17/24 - 2/13/25

Deadline

May 20 2025

Learn More

58

Days Left

UCTT

Ultra Clean Holdings, Inc.

Deadline

May 23 2025

Class Period

5/6/24 - 2/24/25

Allegations

According to the complaint, defendants provided investors with material information concerning the elevated demand from Chinese original equipment manufacturers (OEMs) and in the general Chinese domestic market for Ultra Clean’s products throughout the fiscal year 2024. Defendants’ statements included, among other things, reports of increased demand for the Company’s products and services in the domestic Chinese market and reports of increased revenue, including revenue doubling with no signs of slowing down, due to the elevated demand in China for Ultra Clean’s products and services. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the demand for Ultra Clean’s products and services in the domestic Chinese market; notably, that the Company was facing a customer ramp issue with one of its critical customers, as well as a combination of inventory and demand corrections, which, ultimately, caused weakness for Ultra Clean in China. On February 24, 2025, Ultra Clean published fourth quarter and full year 2024 fiscal results and hosted an associated earnings call, where the Company’s executives revealed that Ultra Clean was facing “demand softness” in China. In particular, Ultra Clean was facing decreased demand in China due to extended qualification timelines and inventory absorption. Investors and analysts reacted immediately to these revelations. The price of Ultra Clean’s common stock declined dramatically. From a closing market price of $36.06 per share on February 24, 2025, Ultra Clean’s stock price fell to $25.90 per share on February 25, 2025, a decline of over 28% in the span a single day.

Class Period

5/6/24 - 2/24/25

Deadline

May 23 2025

Learn More

5

Days Left

IAS

Integral Ad Science Holding Corp.

Deadline

March 31 2025

Class Period

3/2/23 - 2/27/24

Allegations

(i) IAS was experiencing a new material trend of increased competitive pricing pressures and as a result, IAS had been forced to cut prices to compensate for weakening demand and slowing revenue growth; (ii) IAS’s pricing function was no longer “favorable” and IAS could not sustain its pricing and drive price increases; (iii) pricing had become a key differentiator between IAS and its competitor necessary to close major renewals and new deals; (iv) the risks that competition “could result in increased pricing pressure” or “could put pressure on us to change our prices” had in fact transpired; and (v) as a result, the IAS’s public statements were materially false and misleading at all relevant times.

Class Period

3/2/23 - 2/27/24

Deadline

March 31 2025

Learn More

5

Days Left

GO

Grocery Outlet Holding Corp.

Deadline

March 31 2025

Class Period

11/7/23 - 5/7/24

Allegations

According to the complaint, after-market on May 7, 2024, Grocery Outlet announced its financial results for the first quarter of fiscal 2024, published significantly below-expectation guidance for the second quarter, and further reduced its guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on “unforeseen systems transition costs that surfaced at the end of the quarter” and the resulting “residual expense from our commission support program as we finish store physical inventory counts in the second quarter.” Following this news, Grocery Outlet’s stock price fell to $20.88 per share on May 8, 2024, a decline of about 19.38% in the span of just a single day.

Class Period

11/7/23 - 5/7/24

Deadline

March 31 2025

Learn More

5

Days Left

MODV

ModivCare Inc.

Deadline

March 31 2025

Class Period

11/3/22 - 9/15/24

Allegations

According to the filed complaint, defendants made false statements and/or concealed that certain contracts used in ModivCare’s NEMT segment caused the Company’s free cash flow to deteriorate and as a result, (1) contract renegotiations and pricing accommodations negatively impacted the Company’s adjusted EBITDA; (2) the Company had insufficient liquidity; and (3) defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/3/22 - 9/15/24

Deadline

March 31 2025

Learn More

5

Days Left

TIXT

TELUS International (Cda) Inc.

Deadline

March 31 2025

Class Period

2/16/23 - 8/1/24

Allegations

(1) the Company’s AI Data Solutions offerings required the cannibalization of its higher-margin offerings; (2) Telus International’s declining profitability was tied to the Company’s drive to develop AI capabilities; (3) Telus International’s shift toward AI put greater pressure on the Company’s margins than previously disclosed; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

2/16/23 - 8/1/24

Deadline

March 31 2025

Learn More

5

Days Left

WBA

Walgreens Boots Alliance, Inc.

Deadline

March 31 2025

Class Period

4/2/20 - 1/16/25

Allegations

(i) contrary to the Company’s purported commitment to improved regulatory compliance, Walgreens continued to engage in widespread violations of federal law governing the dispensation of prescription medication and reimbursement for the same; (ii) the foregoing conduct, when revealed, would subject Walgreens to a heightened risk of further regulatory scrutiny, civil liability, and reputational harm; (iii) Walgreens’ revenues from the sale of prescription medications were unsustainable to the extent that they derived from unlawful conduct; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

4/2/20 - 1/16/25

Deadline

March 31 2025

Learn More

5

Days Left

ARNC

Arconic Corporation

Deadline

March 31 2025

Class Period

This lawsuit is on behalf of a Class of all persons who sold publicly traded shares of Arconic common stock between April 19, 2022 and May 3, 2023, both dates inclusive.

Allegations

According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that defendants stated in Arconic’s quarterly and annual reports issued during the Class Period that Arconic’s share repurchase programs were “intended to comply with Rule 10b5-1,” which prohibits securities trading on the basis of material nonpublic information, and that all of Arconic’s share purchases “were made in compliance with Rule 10b-18,” which provides a safe harbor for share repurchases that meet certain criteria, but does not provide a safe harbor for insider trading or other violations of the federal securities laws. However, at the time those statements were made, Arconic had made share repurchases while in possession of material nonpublic information, and therefore Arconic’s share repurchase programs were not in compliance with Rule 10b5-1, and the share repurchases were not made in compliance with Rule 10b-18. Further, defendants stated that they were continuing with share repurchases. Inasmuch as the Company was restrained by law from buying back stock during active negotiations with Apollo, the defendants’ statements with respect to ongoing stock repurchases signaled to the market that there were no, and had been no, ongoing negotiations. Accordingly, when speaking about the stock repurchases, the defendants were obligated to disclose the whole truth – that they were in, or had been in, negotiations with Apollo.

Class Period

This lawsuit is on behalf of a Class of all persons who sold publicly traded shares of Arconic common stock between April 19, 2022 and May 3, 2023, both dates inclusive.

Deadline

March 31 2025

Learn More

6

Days Left

NEM

Newmont Corporation

Deadline

April 1 2025

Class Period

2/22/24 - 10/23/24

Allegations

According to the complaint, on October 23, 2024, Newmont published a press release announcing disappointing EBITDA third quarter 2024 highlights, in addition to decreases in production and increases in operating costs. In pertinent part, Newmont revealed that mining operations at its two Tier 1 assets would see lower production than originally guided with expectations of higher costs at these facilities. Following this news, Newmont’s stock price fell from a closing market price of $57.74 per share on October 23, 2024 to $49.25 per share on October 24, 2024.

Class Period

2/22/24 - 10/23/24

Deadline

April 1 2025

Learn More

12

Days Left

NMRA

Neumora Therapeutics, Inc.

Deadline

April 7 2025

Class Period

This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023.

Allegations

(1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn’s original Phase Two trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder, MDD, to show that Navacaprant, Neumora’s flagship therapeutic candidate, offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.

Class Period

This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023.

Deadline

April 7 2025

Learn More

12

Days Left

MPWR

Monolithic Power Systems Inc.

Deadline

April 7 2025

Class Period

2/8/24 - 11/8/24

Allegations

(a) Monolithic’s voltage regulator modules and power management integrated circuits were suffering from significant performance and quality control issues; (b) the defects listed in (a), above, had, in turn, negatively impacted the performance of certain products offered by the Company's largest customer, Nvidia, in which such products were used; (c) Monolithic had failed to adequately address and resolve known issues affecting the performance of the power management solutions the Company supplied to Nvidia; (d) Monolithic’s relationship with Nvidia had been irreparably damaged due to the significant performance and quality control.

Class Period

2/8/24 - 11/8/24

Deadline

April 7 2025

Learn More

12

Days Left

GSK

GSK plc

Deadline

April 7 2025

Class Period

2/5/20 - 8/14/22

Allegations

According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market “[b]ased on information available at the time and correspondence with regulators.” GSK also stated that it was “continuing with investigations into the potential source of NDMA.” Defendants also assured investors that “GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients,” findings that were “consistent with other ranitidine data published prior to 2019.” Finally, defendants claimed that they could not “quantify or reliably estimate the liability.” These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market.

Class Period

2/5/20 - 8/14/22

Deadline

April 7 2025

Learn More

16

Days Left

ICLR

ICON Public Limited Company

Deadline

April 11 2025

Class Period

7/27/23 - 10/23/24

Allegations

(a)ICON was suffering from a material loss of business due to customer cost reduction measures and other widespread funding limitations impacting the Company’s client base; (b)ICON’s purported functional service provision and hybrid model offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand; (d)ICON’s customers had canceled contracts, limited or reduced engagements, delayed clinical trial work, and/or failed to enter into new contracts with ICON for additional clinical trial work at historical rates once existing projects ended (or were scheduled to end) in 2024; (e)ICON’s two largest customers were diversifying their clinical research organization providers away from the Company; (f)as a result of (a)-(e) above, ICON’s reported net new business awards and book-to-bill metrics materially misrepresented client demand for ICON’s services; and (g)as a result of (a)-(f) above, ICON was tracking materially below the 2024 revenue and EPS guidance issued during the Class Period and such guidance lacked a reasonable factual basis.

Class Period

7/27/23 - 10/23/24

Deadline

April 11 2025

Learn More

19

Days Left

ESTC

Elastic N.V.

Deadline

April 14 2025

Class Period

5/31/24 - 8/29/24

Allegations

(i) Elastic had implemented significant changes to its sales operations, particularly with respect to its customer segments in the Americas; (ii) the foregoing changes were likely to, and did, disrupt Elastic’s sales operations during the first quarter of its FY 2025; (iii) accordingly, defendants had overstated the stability of Elastic’s sales operations; (iv) as a result of all the foregoing, Elastic was unlikely to meet its own previously issued revenue guidance for its FY 2025; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

5/31/24 - 8/29/24

Deadline

April 14 2025

Learn More

19

Days Left

NTLA

Intellia Therapeutics, Inc.

Deadline

April 14 2025

Class Period

7/30/24 - 1/8/25

Allegations

According to the complaint, defendants provided investors with material information concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Defendants’ statements included, among other things, confidence in the Company’s timeline for the aforementioned study, specifically that Intellia expected to dose the first patient in the second half of 2024. Defendants failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific research community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain. The truth emerged on January 9, 2025, when Intellia published a press release announcing Company reorganization. In pertinent part, defendants disclosed that Intellia would be halting all NTLA-3001 research and studies and that the Company would be reducing its workforce by 27% in 2025. Specifically, the Company announced that management decided to focus Intellia’s resources on other pharmaceutical development and would be implementing cost saving in the form of a major reduction in force. As a result, defendants pipeline priority readjustment resulted in the Company’s once-touted NTLA-3001’s discontinuation. Following this news, Intellia’s stock price fell from a closing market price of $12.02 per share on January 8, 2025 to $10.20 per share on January 10, 2025.

Class Period

7/30/24 - 1/8/25

Deadline

April 14 2025

Learn More

19

Days Left

EIX

Edison International

Deadline

April 14 2025

Class Period

2/25/21 - 2/6/25

Allegations

(1) Edison’s claim that southern California Edison company used its public safety power shutoffs program to “proactively de-energize power lines to mitigate the risk of catastrophic wildfires during extreme weather events”, was false; (2) this resulted in heightened fire risk in California and heightened legal exposure to the Company; and (3) as a result, defendants’ statements about Edison’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

2/25/21 - 2/6/25

Deadline

April 14 2025

Learn More

19

Days Left

MRK

Merck & Co., Inc.

Deadline

April 14 2025

Class Period

2/3/22 - 2/3/25

Allegations

According to the complaint, defendants provided investors with material information concerning Merck’s expected revenue of $11 billion from sales of Gardasil by 2030. Defendants’ statements included, among other things, confidence in Merck’s purported ability to utilize successful consumer activation and education efforts on the benefits of Gardasil in order to drive demand and capitalize on eligible populations for vaccination, resulting in confidently optimistic reports and forecasts of Gardasil’s growth in China. The full truth finally emerged on February 4, 2025, when Merck announced it would no longer achieve the long-forecasted $11 billion in sales of Gardasil by 2030, as it would cease shipments of Gardasil to China “through at least midyear” to facilitate a “rapid reduction of inventory.” Defendants claimed this was necessitated by the continued over-inflation of overall channel inventories as demand in China for Gardasil had “not recovered to the level we had expected.” Following this news, Merck’s common stock declined dramatically. From a closing market price of $99.79 per share on February 3, 2025, Merck’s stock price fell to $90.74 per share on February 4, 2025, a decline of more than 9% in the span of just a single day.

Class Period

2/3/22 - 2/3/25

Deadline

April 14 2025

Learn More

19

Days Left

FMC

FMC Corporation

Deadline

April 14 2025

Class Period

11/16/23 - 2/4/25

Allegations

(1) the Company’s channel management initiatives were not progressing as represented; (2) faced with pricing pressure, the Company had made the decision not to compete on prices and instead walk away from sales opportunities; (3) the Company had inflated inventory in the channels in “Latin America, including Brazil, Asia, including India, as well as Canada and Eastern Europe;” and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/16/23 - 2/4/25

Deadline

April 14 2025

Learn More

20

Days Left

TMDX

TransMedics Group, Inc.

Deadline

April 15 2025

Class Period

2/28/23 - 1/10/25

Allegations

(1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

2/28/23 - 1/10/25

Deadline

April 15 2025

Learn More

20

Days Left

ALAR

Alarum Technologies Ltd.

Deadline

April 15 2025

Class Period

3/14/24 - 8/26/24

Allegations

(i) the Company was less effective in retaining and/or expanding customer engagements than it had represented to investors; (ii) the foregoing would impair Alarum’s ability to generate consistent revenue growth; (iii) accordingly, Alarum’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

3/14/24 - 8/26/24

Deadline

April 15 2025

Learn More

23

Days Left

VG

Venture Global, Inc.

Deadline

April 18 2025

Class Period

This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Venture’s registration statement for the initial public offering held on or about January 24, 2025.

Allegations

According to the complaint, Venture completed its initial public offering on January 27, 2025, selling 70 million shares at $24.00 per share. On February 5, 2025, TotalEnergies, an energy company that was a target customer of Venture, rejected opportunities to become a long-term customer of Venture, citing lack of trust. In particular, TotalEnergies CEO, stated that he was approached by Venture to see if the company would be interested in a long-term supply contract for liquefied natural gas from the Calcasieu Pass terminal in Louisiana, but he rejected the offer “because of what they are doing.” Venture is currently facing legal challenges from existing large clients, such as BP and Shell, due to delays in supply contracts as Venture commissions its projects. Given the fact that defendants ability to deliver liquefied natural gas (LNG) to the world and to continue development of Venture’s five natural gas liquefication and export projects depends on customer contracts, defendants’ failure to account for and address these issues caused statements in Venture’s registration statement to be false and/or materially misleading at the time of the initial public offering.

Class Period

This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Venture’s registration statement for the initial public offering held on or about January 24, 2025.

Deadline

April 18 2025

Learn More

26

Days Left

STZ

Constellation Brands, Inc.

Deadline

April 21 2025

Class Period

4/11/24 - 1/8/25

Allegations

According to the complaint, defendants provided investors with material information concerning Constellation’s full year 2024 fiscal results and financial outlook for 2025 which was based in material part on defendants enhanced focus on improving mix, inventory and sales execution in its Wine and Spirits business, specifically focusing efforts within its premium and above brands to drive more consistent growth. Additionally, defendants made investments in media spend and price promotions as well as adjustments in sales capabilities to support distributor partners. On January 8, 2025 defendants issued a press release announcing the Company’s third quarter fiscal year 2025 results. In pertinent part, defendants presented a significant miss on sales performance in the Beer segment and an even steeper miss for the Wine & Spirits. Following this news, the price of Constellation’s common stock declined dramatically. From a closing market price of $219.28 per share on January 8, 2025 to $181.81 per share on January 10, 2025.

Class Period

4/11/24 - 1/8/25

Deadline

April 21 2025

Learn More

26

Days Left

TTD

The Trade Desk, Inc.

Deadline

April 21 2025

Class Period

5/9/24 - 2/12/25

Allegations

(1) Trade Desk was experiencing significant, ongoing, self-inflicted execution challenges rolling out the Company's AI forecasting tool, Kokai, including transitioning clients to Kokai from the Company’s older platform Solimar; (2) such execution challenges meaningfully delayed the Kokai Rollout; (3) Trade Desk’s inability to effectively execute the Kokai Rollout negatively impacted the Company’s business and operations, particularly revenue growth; and (4) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

5/9/24 - 2/12/25

Deadline

April 21 2025

Learn More

27

Days Left

SMTC

Semtech Corporation

Deadline

April 22 2025

Class Period

8/27/24 - 2/7/25

Allegations

(1) its CopperEdge products did not meet the needs of its server rack customer or end users; (2) as a result, the CopperEdge products required certain rack architecture changes; (3) as a result of the foregoing, the Company’s sales of CopperEdge products would not ramp-up during fiscal 2026; (4) as a result, sales of CopperEdge products would be lower-than-expected; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

8/27/24 - 2/7/25

Deadline

April 22 2025

Learn More

28

Days Left

ATKR

Atkore Inc.

Deadline

April 23 2025

Class Period

2/1/24 - 2/3/25

Allegations

(1) Atkore engaged in an anticompetitive price-fixing scheme that artificially inflated the price of PVC Pipes; (2) Atkore reaped significant, unsustainable financial benefits from its anticompetitive conduct; (3) as Atkore’s price-fixing scheme was exposed, the Company and its price-fixing co-conspirators were no longer able to artificially inflate the price of PVC Pipes, resulting in a substantial decrease in the price of PVC Pipes; (4) Atkore’s business and operations were negatively impacted; and (5) as a result, defendants’ positive statements Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

2/1/24 - 2/3/25

Deadline

April 23 2025

Learn More

33

Days Left

QUBT

Quantum Computing Inc.

Deadline

April 28 2025

Class Period

3/30/20 - 1/15/25

Allegations

(i) defendants overstated the capabilities of QCI’s quantum computing technologies, products, and/or services; (ii) defendants overstated the scope and nature of QCI’s relationship with NASA, as well as the scope and nature of QCI’s NASA-related contracts and/or subcontracts; (iii) defendants overstated QCI’s progress in developing a thin film lithium niobate, TFLN foundry, the scale of the purported TFLN foundry, and orders for the Company’s TFLN chips; (iv) QCI’s business dealings with Quad M and millionways both qualified as related party transactions; (v) accordingly, QCI’s revenues relied, at least in part, on undisclosed related party transactions; (vi) all the foregoing, once revealed, was likely to have a significant negative impact on QCI’s business and reputation; and (vii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

3/30/20 - 1/15/25

Deadline

April 28 2025

Learn More

33

Days Left

MANH

Manhattan Associates, Inc.

Deadline

April 28 2025

Class Period

10/22/24 - 1/28/25

Allegations

According to the complaint, defendants provided investors with material information concerning Manhattan Associates’ expected revenue for the fiscal year 2025. Defendants’ statements included, among other things, confidence in the Company’s ability to forecast guidance despite macroeconomic fluctuations, the growth potential of their professional services offerings, and the ability for their cloud revenue to drive revenue for its professional services. On January 28, 2025, Manhattan Associates published its financial results for the fourth quarter and full fiscal year 2024 and announced reduced revenue guidance for the full fiscal year 2025. The Company attributed its results and lowered guidance on the “shift in professional services work to future periods . . . and to a lesser extent, reduced customization and higher partner utilization.” Following this news, the price of Manhattan Associates’ common stock declined dramatically from a closing market price of $295.10 per share on January 28, 2025, to $222.84 per share on January 29, 2025, a decline of about 24.49% in the span of just a single day.

Class Period

10/22/24 - 1/28/25

Deadline

April 28 2025

Learn More

33

Days Left

RKLB

Rocket Lab USA, Inc.

Deadline

April 28 2025

Class Period

11/12/24 - 2/25/25

Allegations

(1) the Company’s plans for three barge landing tests were significantly delayed; (2) a critical potable water problem was not scheduled to be fixed until January 2026, which delayed preparation of the launch pad; (3) as a result of the foregoing, there was a substantial risk that Rocket Lab’s Neutron rocket would not launch in mid-2025; (4) Neutron’s only contract was made at a discount with an unreliable partner; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/12/24 - 2/25/25

Deadline

April 28 2025

Learn More

40

Days Left

ELF

e.l.f. Beauty, Inc.

Deadline

May 5 2025

Class Period

11/1/23 - 11/19/24

Allegations

(i) contrary to its representations to investors, the Company was experiencing rising inventory levels as a consequence of flagging sales; (ii) Elf falsely attributed the rising inventory levels to, among other things, changes in its sourcing practices; (iii) to maintain investor confidence, Elf reported inflated revenue, profits, and inventory over several quarters; (iv) the Company’s business and/or financial prospects were overstated; (v) all of the foregoing, once revealed, would likely have a material negative impact on the Company; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

11/1/23 - 11/19/24

Deadline

May 5 2025

Learn More

40

Days Left

SWKS

Skyworks Solutions, Inc.

Deadline

May 5 2025

Class Period

7/30/24 - 2/5/25

Allegations

According to the complaint, defendants provided investors with material information concerning Skyworks’ expected revenue for the fiscal year 2025. Defendants’ statements included, among other things, confidence in Skyworks’ ability to expand its mobile business and capitalize on its growth potential by investing in new technologies to diversify its portfolio of offerings. On February 5, 2025, after market close, Skyworks announced its financial results for the first quarter of fiscal year 2025 and provided lower-than anticipated revenue guidance for the second quarter of fiscal year 2025. The Company attributed its results and low guidance to a “competitive landscape” that had “intensified” in recent years. Following this news, the price of Skyworks’ common stock declined dramatically. From a closing market price of $87.08 per share on February 5, 2025, Skyworks’ stock price fell to $65.60 per share on February 6, 2025, a decline of over 24% in the span of just a single day.

Class Period

7/30/24 - 2/5/25

Deadline

May 5 2025

Learn More

40

Days Left

APP

AppLovin Corporation

Deadline

May 5 2025

Class Period

5/10/23 - 2/25/25

Allegations

According to the complaint, defendants provided investors with material information concerning AppLovin’s financial growth and stability. Defendants’ statements included, among other things, confidence in AppLovin’s launch of its AXON 2.0 digital ad platform and using “cutting-edge AI technologies” to more efficiently match advertisements to mobile games, in addition to expanding into web-based marketing and e-commerce. Moreover, defendants publicly reported impressive financial results, outlooks, and guidance to investors, all while using dishonest advertising practices. The truth emerged on February 26, 2025, when analyst research reports emerged stating that AppLovin was reverse engineering and exploiting advertising data from Meta Platforms. The reports further alleged AppLovin was utilizing manipulative practices to artificially inflate their own ad click-through and app download rates, such as by having ads click on themselves or utilizing design gimmicks to trigger forced shadow downloads, erroneously inflating installation numbers and, in turn, its profit figures. Following this news, the price of AppLovin’s stock declined from $377.06 per share on February 25, 2025 to $331.00 per share on February 26, 2025.

Class Period

5/10/23 - 2/25/25

Deadline

May 5 2025

Learn More

40

Days Left

MRVI

Maravai LifeSciences Holdings, Inc.

Deadline

May 5 2025

Class Period

8/7/24 - 2/24/25

Allegations

(1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024; (3) its goodwill was overstated; and (4)as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

8/7/24 - 2/24/25

Deadline

May 5 2025

Learn More

40

Days Left

RC

Ready Capital Corporation

Deadline

May 5 2025

Class Period

11/7/24 - 3/2/25

Allegations

(1) significant non-performing loans in its CRE portfolio were not likely to be collectible; (2) Ready Capital would fully reserve these problem loans in order to “stabilize” its CRE portfolio; (3) this was not accurately reflected in Ready Capital’s current expected credit loss or valuation allowances; (4) as a result, the Company’s financial results would be adversely affected; and (5), as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/7/24 - 3/2/25

Deadline

May 5 2025

Learn More

44

Days Left

NEP

XPLR Infrastructure, LP

Deadline

May 9 2025

Class Period

1/26/21 - 1/27/25

Allegations

(i) XPLR was struggling to maintain its operations as a yieldco; (ii) defendants temporarily relieved this issue by entering into CEPF, convertible equity portfolio financing arrangements while downplaying the attendant risks; (iii) XPLR could not buy out CEPFs before their maturity date without risking significant unitholder dilution; (iv) as a result, defendants planned to halt cash distributions to investors and instead redirect those funds to, inter alia, buy out the Company’s CEPFs; (v) as a result of all the foregoing, XPLR’s yieldco business model and distribution growth rate was unsustainable; and (vi) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

1/26/21 - 1/27/25

Deadline

May 9 2025

Learn More

44

Days Left

DMRC

Digimarc Corporation

Deadline

May 9 2025

Class Period

5/2/24 - 2/26/25

Allegations

(1) a large commercial partner would not renew a large contract on the same terms; (2) as a result, Digimarc would renegotiate the large commercial contract; (3) as a result of the foregoing, the Company’s subscription revenue and annual recurring revenue would be adversely affected; (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/2/24 - 2/26/25

Deadline

May 9 2025

Learn More

47

Days Left

FLNC

Fluence Energy, Inc.

Deadline

May 12 2025

Class Period

11/29/23 - 2/10/25

Allegations

(1) Fluence’s relationship with its founders and largest sources of revenue, Siemens AG and The AES Corporation, was poised to decline; (2) Siemens Energy, Siemens AG’s U.S. affiliate, had accused the Company of engineering failures and fraud; (3) Fluence’s margins and revenue growth were inflated as Siemens and AES were moving to divest; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements related to Fluence’s battery energy storage business, as well as related financial results, growth, and prospects.

Class Period

11/29/23 - 2/10/25

Deadline

May 12 2025

Learn More

47

Days Left

GERN

Geron Corporation

Deadline

May 12 2025

Class Period

6/7/24 - 2/25/25

Allegations

According to the complaint, defendants provided investors with material information concerning defendants’ expectations for the launch and growth potential of Rytelo (imetelstat). Defendants’ statements included, among other things, confidence in Geron’s ability to capitalize on the purportedly significant unmet need for the drug and to execute on its commercial plan to target first-line ESA ineligible patients, while continually minimizing the risks associated with the burden of the weekly monitoring requirement for Rytelo and the impacts of seasonality and existing competition on the drug’s sales. On February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal 2024, disclosing that Rytelo’s growth had flattened over the preceding months. The Company attributed the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. Following this news, the price of Geron’s common stock declined dramatically. From a closing market price of $2.37 per share on February 25, 2025, Geron’s stock price fell to $1.61 per share on February 26, 2025, a decline of about 32.07% in the span of just a single day.

Class Period

6/7/24 - 2/25/25

Deadline

May 12 2025

Learn More

48

Days Left

TFII

TFI International Inc.

Deadline

May 13 2025

Class Period

4/26/24 - 2/19/25

Allegations

(1) the Company was losing small and medium business customers; (2) as a result, the Company’s TForce revenue was declining; (3) TFI was experiencing difficulties managing its costs; (4) as a result of the foregoing, the profitability of its largest business segment was declining; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

4/26/24 - 2/19/25

Deadline

May 13 2025

Learn More

48

Days Left

EU

enCore Energy Corp.

Deadline

May 13 2025

Class Period

3/28/24 - 3/2/25

Allegations

(1) enCore lacked effective internal controls over financial reporting; (2) enCore could not capitalize certain exploratory and development costs under GAAP; (3) as a result, its net losses had substantially increased; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

3/28/24 - 3/2/25

Deadline

May 13 2025

Learn More

54

Days Left

ZYXI

Zynex, Inc.

Deadline

May 19 2025

Class Period

3/13/23 - 3/11/25

Allegations

(1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, the Company inflated its revenue; (3) the Company’s practice of filing false claims drew scrutiny from insurers, including the U.S. military health insurance program, Tricare; (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

3/13/23 - 3/11/25

Deadline

May 19 2025

Learn More

55

Days Left

SANA

Sana Biotechnology, Inc.

Deadline

May 20 2025

Class Period

3/17/23 - 11/4/24

Allegations

(i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (iv) accordingly, defendants overstated Sana’s financial capacity to maintain its current operations and advance its existing product candidates; and (v) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

3/17/23 - 11/4/24

Deadline

May 20 2025

Learn More

55

Days Left

PPTA

Perpetua Resources Corp.

Deadline

May 20 2025

Class Period

4/17/24 - 2/13/25

Allegations

According to the complaint, defendants provided investors with material information concerning Perpetua’s expected initial capital expenditure for the Stibnite Gold Project. Defendants’ statements included, among other things, minimization of the impact of inflation and other potential sources for increased capital expenditure costs for the project. On February 13, 2025, Perpetua published an updated cash flow model for the Stibnite Gold Project, unveiling additional capital expenses of $952 million, a more than 75% increase from the original figures presented to investors and well beyond the suggested 10-20% increase contemplated by defendants. The Company attributed these increased costs on inflation, indirect costs, higher mining costs, and direct decisions defendants made with respect to the project, including the choice to change the design of the electrical poles from timber to steel and the decision to “buy-and-build instead of lease the oxygen plant.” Following this news, the price of Perpetua’s common stock declined dramatically. From a closing market price of $11.97 per share on February 13, 2025, Perpetua’s stock price fell to $9.29 per share on February 14, 2025, a decline of about 22.39% in the span of just a single day.

Class Period

4/17/24 - 2/13/25

Deadline

May 20 2025

Learn More

58

Days Left

UCTT

Ultra Clean Holdings, Inc.

Deadline

May 23 2025

Class Period

5/6/24 - 2/24/25

Allegations

According to the complaint, defendants provided investors with material information concerning the elevated demand from Chinese original equipment manufacturers (OEMs) and in the general Chinese domestic market for Ultra Clean’s products throughout the fiscal year 2024. Defendants’ statements included, among other things, reports of increased demand for the Company’s products and services in the domestic Chinese market and reports of increased revenue, including revenue doubling with no signs of slowing down, due to the elevated demand in China for Ultra Clean’s products and services. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the demand for Ultra Clean’s products and services in the domestic Chinese market; notably, that the Company was facing a customer ramp issue with one of its critical customers, as well as a combination of inventory and demand corrections, which, ultimately, caused weakness for Ultra Clean in China. On February 24, 2025, Ultra Clean published fourth quarter and full year 2024 fiscal results and hosted an associated earnings call, where the Company’s executives revealed that Ultra Clean was facing “demand softness” in China. In particular, Ultra Clean was facing decreased demand in China due to extended qualification timelines and inventory absorption. Investors and analysts reacted immediately to these revelations. The price of Ultra Clean’s common stock declined dramatically. From a closing market price of $36.06 per share on February 24, 2025, Ultra Clean’s stock price fell to $25.90 per share on February 25, 2025, a decline of over 28% in the span a single day.

Class Period

5/6/24 - 2/24/25

Deadline

May 23 2025

Learn More

5

Days Left

IAS

Integral Ad Science Holding Corp.

Deadline

March 31 2025

Class Period

3/2/23 - 2/27/24

Allegations

(i) IAS was experiencing a new material trend of increased competitive pricing pressures and as a result, IAS had been forced to cut prices to compensate for weakening demand and slowing revenue growth; (ii) IAS’s pricing function was no longer “favorable” and IAS could not sustain its pricing and drive price increases; (iii) pricing had become a key differentiator between IAS and its competitor necessary to close major renewals and new deals; (iv) the risks that competition “could result in increased pricing pressure” or “could put pressure on us to change our prices” had in fact transpired; and (v) as a result, the IAS’s public statements were materially false and misleading at all relevant times.

Class Period

3/2/23 - 2/27/24

Deadline

March 31 2025

Learn More

5

Days Left

GO

Grocery Outlet Holding Corp.

Deadline

March 31 2025

Class Period

11/7/23 - 5/7/24

Allegations

According to the complaint, after-market on May 7, 2024, Grocery Outlet announced its financial results for the first quarter of fiscal 2024, published significantly below-expectation guidance for the second quarter, and further reduced its guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on “unforeseen systems transition costs that surfaced at the end of the quarter” and the resulting “residual expense from our commission support program as we finish store physical inventory counts in the second quarter.” Following this news, Grocery Outlet’s stock price fell to $20.88 per share on May 8, 2024, a decline of about 19.38% in the span of just a single day.

Class Period

11/7/23 - 5/7/24

Deadline

March 31 2025

Learn More

5

Days Left

MODV

ModivCare Inc.

Deadline

March 31 2025

Class Period

11/3/22 - 9/15/24

Allegations

According to the filed complaint, defendants made false statements and/or concealed that certain contracts used in ModivCare’s NEMT segment caused the Company’s free cash flow to deteriorate and as a result, (1) contract renegotiations and pricing accommodations negatively impacted the Company’s adjusted EBITDA; (2) the Company had insufficient liquidity; and (3) defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/3/22 - 9/15/24

Deadline

March 31 2025

Learn More

5

Days Left

TIXT

TELUS International (Cda) Inc.

Deadline

March 31 2025

Class Period

2/16/23 - 8/1/24

Allegations

(1) the Company’s AI Data Solutions offerings required the cannibalization of its higher-margin offerings; (2) Telus International’s declining profitability was tied to the Company’s drive to develop AI capabilities; (3) Telus International’s shift toward AI put greater pressure on the Company’s margins than previously disclosed; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

2/16/23 - 8/1/24

Deadline

March 31 2025

Learn More

5

Days Left

WBA

Walgreens Boots Alliance, Inc.

Deadline

March 31 2025

Class Period

4/2/20 - 1/16/25

Allegations

(i) contrary to the Company’s purported commitment to improved regulatory compliance, Walgreens continued to engage in widespread violations of federal law governing the dispensation of prescription medication and reimbursement for the same; (ii) the foregoing conduct, when revealed, would subject Walgreens to a heightened risk of further regulatory scrutiny, civil liability, and reputational harm; (iii) Walgreens’ revenues from the sale of prescription medications were unsustainable to the extent that they derived from unlawful conduct; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

4/2/20 - 1/16/25

Deadline

March 31 2025

Learn More

5

Days Left

ARNC

Arconic Corporation

Deadline

March 31 2025

Class Period

This lawsuit is on behalf of a Class of all persons who sold publicly traded shares of Arconic common stock between April 19, 2022 and May 3, 2023, both dates inclusive.

Allegations

According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that defendants stated in Arconic’s quarterly and annual reports issued during the Class Period that Arconic’s share repurchase programs were “intended to comply with Rule 10b5-1,” which prohibits securities trading on the basis of material nonpublic information, and that all of Arconic’s share purchases “were made in compliance with Rule 10b-18,” which provides a safe harbor for share repurchases that meet certain criteria, but does not provide a safe harbor for insider trading or other violations of the federal securities laws. However, at the time those statements were made, Arconic had made share repurchases while in possession of material nonpublic information, and therefore Arconic’s share repurchase programs were not in compliance with Rule 10b5-1, and the share repurchases were not made in compliance with Rule 10b-18. Further, defendants stated that they were continuing with share repurchases. Inasmuch as the Company was restrained by law from buying back stock during active negotiations with Apollo, the defendants’ statements with respect to ongoing stock repurchases signaled to the market that there were no, and had been no, ongoing negotiations. Accordingly, when speaking about the stock repurchases, the defendants were obligated to disclose the whole truth – that they were in, or had been in, negotiations with Apollo.

Class Period

This lawsuit is on behalf of a Class of all persons who sold publicly traded shares of Arconic common stock between April 19, 2022 and May 3, 2023, both dates inclusive.

Deadline

March 31 2025

Learn More

6

Days Left

NEM

Newmont Corporation

Deadline

April 1 2025

Class Period

2/22/24 - 10/23/24

Allegations

According to the complaint, on October 23, 2024, Newmont published a press release announcing disappointing EBITDA third quarter 2024 highlights, in addition to decreases in production and increases in operating costs. In pertinent part, Newmont revealed that mining operations at its two Tier 1 assets would see lower production than originally guided with expectations of higher costs at these facilities. Following this news, Newmont’s stock price fell from a closing market price of $57.74 per share on October 23, 2024 to $49.25 per share on October 24, 2024.

Class Period

2/22/24 - 10/23/24

Deadline

April 1 2025

Learn More

12

Days Left

NMRA

Neumora Therapeutics, Inc.

Deadline

April 7 2025

Class Period

This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023.

Allegations

(1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn’s original Phase Two trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder, MDD, to show that Navacaprant, Neumora’s flagship therapeutic candidate, offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.

Class Period

This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023.

Deadline

April 7 2025

Learn More

12

Days Left

MPWR

Monolithic Power Systems Inc.

Deadline

April 7 2025

Class Period

2/8/24 - 11/8/24

Allegations

(a) Monolithic’s voltage regulator modules and power management integrated circuits were suffering from significant performance and quality control issues; (b) the defects listed in (a), above, had, in turn, negatively impacted the performance of certain products offered by the Company's largest customer, Nvidia, in which such products were used; (c) Monolithic had failed to adequately address and resolve known issues affecting the performance of the power management solutions the Company supplied to Nvidia; (d) Monolithic’s relationship with Nvidia had been irreparably damaged due to the significant performance and quality control.

Class Period

2/8/24 - 11/8/24

Deadline

April 7 2025

Learn More

12

Days Left

GSK

GSK plc

Deadline

April 7 2025

Class Period

2/5/20 - 8/14/22

Allegations

According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market “[b]ased on information available at the time and correspondence with regulators.” GSK also stated that it was “continuing with investigations into the potential source of NDMA.” Defendants also assured investors that “GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients,” findings that were “consistent with other ranitidine data published prior to 2019.” Finally, defendants claimed that they could not “quantify or reliably estimate the liability.” These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market.

Class Period

2/5/20 - 8/14/22

Deadline

April 7 2025

Learn More

16

Days Left

ICLR

ICON Public Limited Company

Deadline

April 11 2025

Class Period

7/27/23 - 10/23/24

Allegations

(a)ICON was suffering from a material loss of business due to customer cost reduction measures and other widespread funding limitations impacting the Company’s client base; (b)ICON’s purported functional service provision and hybrid model offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand; (d)ICON’s customers had canceled contracts, limited or reduced engagements, delayed clinical trial work, and/or failed to enter into new contracts with ICON for additional clinical trial work at historical rates once existing projects ended (or were scheduled to end) in 2024; (e)ICON’s two largest customers were diversifying their clinical research organization providers away from the Company; (f)as a result of (a)-(e) above, ICON’s reported net new business awards and book-to-bill metrics materially misrepresented client demand for ICON’s services; and (g)as a result of (a)-(f) above, ICON was tracking materially below the 2024 revenue and EPS guidance issued during the Class Period and such guidance lacked a reasonable factual basis.

Class Period

7/27/23 - 10/23/24

Deadline

April 11 2025

Learn More

19

Days Left

ESTC

Elastic N.V.

Deadline

April 14 2025

Class Period

5/31/24 - 8/29/24

Allegations

(i) Elastic had implemented significant changes to its sales operations, particularly with respect to its customer segments in the Americas; (ii) the foregoing changes were likely to, and did, disrupt Elastic’s sales operations during the first quarter of its FY 2025; (iii) accordingly, defendants had overstated the stability of Elastic’s sales operations; (iv) as a result of all the foregoing, Elastic was unlikely to meet its own previously issued revenue guidance for its FY 2025; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

5/31/24 - 8/29/24

Deadline

April 14 2025

Learn More

19

Days Left

NTLA

Intellia Therapeutics, Inc.

Deadline

April 14 2025

Class Period

7/30/24 - 1/8/25

Allegations

According to the complaint, defendants provided investors with material information concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Defendants’ statements included, among other things, confidence in the Company’s timeline for the aforementioned study, specifically that Intellia expected to dose the first patient in the second half of 2024. Defendants failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific research community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain. The truth emerged on January 9, 2025, when Intellia published a press release announcing Company reorganization. In pertinent part, defendants disclosed that Intellia would be halting all NTLA-3001 research and studies and that the Company would be reducing its workforce by 27% in 2025. Specifically, the Company announced that management decided to focus Intellia’s resources on other pharmaceutical development and would be implementing cost saving in the form of a major reduction in force. As a result, defendants pipeline priority readjustment resulted in the Company’s once-touted NTLA-3001’s discontinuation. Following this news, Intellia’s stock price fell from a closing market price of $12.02 per share on January 8, 2025 to $10.20 per share on January 10, 2025.

Class Period

7/30/24 - 1/8/25

Deadline

April 14 2025

Learn More

19

Days Left

EIX

Edison International

Deadline

April 14 2025

Class Period

2/25/21 - 2/6/25

Allegations

(1) Edison’s claim that southern California Edison company used its public safety power shutoffs program to “proactively de-energize power lines to mitigate the risk of catastrophic wildfires during extreme weather events”, was false; (2) this resulted in heightened fire risk in California and heightened legal exposure to the Company; and (3) as a result, defendants’ statements about Edison’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

2/25/21 - 2/6/25

Deadline

April 14 2025

Learn More

19

Days Left

MRK

Merck & Co., Inc.

Deadline

April 14 2025

Class Period

2/3/22 - 2/3/25

Allegations

According to the complaint, defendants provided investors with material information concerning Merck’s expected revenue of $11 billion from sales of Gardasil by 2030. Defendants’ statements included, among other things, confidence in Merck’s purported ability to utilize successful consumer activation and education efforts on the benefits of Gardasil in order to drive demand and capitalize on eligible populations for vaccination, resulting in confidently optimistic reports and forecasts of Gardasil’s growth in China. The full truth finally emerged on February 4, 2025, when Merck announced it would no longer achieve the long-forecasted $11 billion in sales of Gardasil by 2030, as it would cease shipments of Gardasil to China “through at least midyear” to facilitate a “rapid reduction of inventory.” Defendants claimed this was necessitated by the continued over-inflation of overall channel inventories as demand in China for Gardasil had “not recovered to the level we had expected.” Following this news, Merck’s common stock declined dramatically. From a closing market price of $99.79 per share on February 3, 2025, Merck’s stock price fell to $90.74 per share on February 4, 2025, a decline of more than 9% in the span of just a single day.

Class Period

2/3/22 - 2/3/25

Deadline

April 14 2025

Learn More

19

Days Left

FMC

FMC Corporation

Deadline

April 14 2025

Class Period

11/16/23 - 2/4/25

Allegations

(1) the Company’s channel management initiatives were not progressing as represented; (2) faced with pricing pressure, the Company had made the decision not to compete on prices and instead walk away from sales opportunities; (3) the Company had inflated inventory in the channels in “Latin America, including Brazil, Asia, including India, as well as Canada and Eastern Europe;” and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/16/23 - 2/4/25

Deadline

April 14 2025

Learn More

20

Days Left

TMDX

TransMedics Group, Inc.

Deadline

April 15 2025

Class Period

2/28/23 - 1/10/25

Allegations

(1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

2/28/23 - 1/10/25

Deadline

April 15 2025

Learn More

20

Days Left

ALAR

Alarum Technologies Ltd.

Deadline

April 15 2025

Class Period

3/14/24 - 8/26/24

Allegations

(i) the Company was less effective in retaining and/or expanding customer engagements than it had represented to investors; (ii) the foregoing would impair Alarum’s ability to generate consistent revenue growth; (iii) accordingly, Alarum’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

3/14/24 - 8/26/24

Deadline

April 15 2025

Learn More

23

Days Left

VG

Venture Global, Inc.

Deadline

April 18 2025

Class Period

This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Venture’s registration statement for the initial public offering held on or about January 24, 2025.

Allegations

According to the complaint, Venture completed its initial public offering on January 27, 2025, selling 70 million shares at $24.00 per share. On February 5, 2025, TotalEnergies, an energy company that was a target customer of Venture, rejected opportunities to become a long-term customer of Venture, citing lack of trust. In particular, TotalEnergies CEO, stated that he was approached by Venture to see if the company would be interested in a long-term supply contract for liquefied natural gas from the Calcasieu Pass terminal in Louisiana, but he rejected the offer “because of what they are doing.” Venture is currently facing legal challenges from existing large clients, such as BP and Shell, due to delays in supply contracts as Venture commissions its projects. Given the fact that defendants ability to deliver liquefied natural gas (LNG) to the world and to continue development of Venture’s five natural gas liquefication and export projects depends on customer contracts, defendants’ failure to account for and address these issues caused statements in Venture’s registration statement to be false and/or materially misleading at the time of the initial public offering.

Class Period

This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Venture’s registration statement for the initial public offering held on or about January 24, 2025.

Deadline

April 18 2025

Learn More

26

Days Left

STZ

Constellation Brands, Inc.

Deadline

April 21 2025

Class Period

4/11/24 - 1/8/25

Allegations

According to the complaint, defendants provided investors with material information concerning Constellation’s full year 2024 fiscal results and financial outlook for 2025 which was based in material part on defendants enhanced focus on improving mix, inventory and sales execution in its Wine and Spirits business, specifically focusing efforts within its premium and above brands to drive more consistent growth. Additionally, defendants made investments in media spend and price promotions as well as adjustments in sales capabilities to support distributor partners. On January 8, 2025 defendants issued a press release announcing the Company’s third quarter fiscal year 2025 results. In pertinent part, defendants presented a significant miss on sales performance in the Beer segment and an even steeper miss for the Wine & Spirits. Following this news, the price of Constellation’s common stock declined dramatically. From a closing market price of $219.28 per share on January 8, 2025 to $181.81 per share on January 10, 2025.

Class Period

4/11/24 - 1/8/25

Deadline

April 21 2025

Learn More

26

Days Left

TTD

The Trade Desk, Inc.

Deadline

April 21 2025

Class Period

5/9/24 - 2/12/25

Allegations

(1) Trade Desk was experiencing significant, ongoing, self-inflicted execution challenges rolling out the Company's AI forecasting tool, Kokai, including transitioning clients to Kokai from the Company’s older platform Solimar; (2) such execution challenges meaningfully delayed the Kokai Rollout; (3) Trade Desk’s inability to effectively execute the Kokai Rollout negatively impacted the Company’s business and operations, particularly revenue growth; and (4) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

5/9/24 - 2/12/25

Deadline

April 21 2025

Learn More

27

Days Left

SMTC

Semtech Corporation

Deadline

April 22 2025

Class Period

8/27/24 - 2/7/25

Allegations

(1) its CopperEdge products did not meet the needs of its server rack customer or end users; (2) as a result, the CopperEdge products required certain rack architecture changes; (3) as a result of the foregoing, the Company’s sales of CopperEdge products would not ramp-up during fiscal 2026; (4) as a result, sales of CopperEdge products would be lower-than-expected; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

8/27/24 - 2/7/25

Deadline

April 22 2025

Learn More

28

Days Left

ATKR

Atkore Inc.

Deadline

April 23 2025

Class Period

2/1/24 - 2/3/25

Allegations

(1) Atkore engaged in an anticompetitive price-fixing scheme that artificially inflated the price of PVC Pipes; (2) Atkore reaped significant, unsustainable financial benefits from its anticompetitive conduct; (3) as Atkore’s price-fixing scheme was exposed, the Company and its price-fixing co-conspirators were no longer able to artificially inflate the price of PVC Pipes, resulting in a substantial decrease in the price of PVC Pipes; (4) Atkore’s business and operations were negatively impacted; and (5) as a result, defendants’ positive statements Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

2/1/24 - 2/3/25

Deadline

April 23 2025

Learn More

33

Days Left

QUBT

Quantum Computing Inc.

Deadline

April 28 2025

Class Period

3/30/20 - 1/15/25

Allegations

(i) defendants overstated the capabilities of QCI’s quantum computing technologies, products, and/or services; (ii) defendants overstated the scope and nature of QCI’s relationship with NASA, as well as the scope and nature of QCI’s NASA-related contracts and/or subcontracts; (iii) defendants overstated QCI’s progress in developing a thin film lithium niobate, TFLN foundry, the scale of the purported TFLN foundry, and orders for the Company’s TFLN chips; (iv) QCI’s business dealings with Quad M and millionways both qualified as related party transactions; (v) accordingly, QCI’s revenues relied, at least in part, on undisclosed related party transactions; (vi) all the foregoing, once revealed, was likely to have a significant negative impact on QCI’s business and reputation; and (vii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

3/30/20 - 1/15/25

Deadline

April 28 2025

Learn More

33

Days Left

MANH

Manhattan Associates, Inc.

Deadline

April 28 2025

Class Period

10/22/24 - 1/28/25

Allegations

According to the complaint, defendants provided investors with material information concerning Manhattan Associates’ expected revenue for the fiscal year 2025. Defendants’ statements included, among other things, confidence in the Company’s ability to forecast guidance despite macroeconomic fluctuations, the growth potential of their professional services offerings, and the ability for their cloud revenue to drive revenue for its professional services. On January 28, 2025, Manhattan Associates published its financial results for the fourth quarter and full fiscal year 2024 and announced reduced revenue guidance for the full fiscal year 2025. The Company attributed its results and lowered guidance on the “shift in professional services work to future periods . . . and to a lesser extent, reduced customization and higher partner utilization.” Following this news, the price of Manhattan Associates’ common stock declined dramatically from a closing market price of $295.10 per share on January 28, 2025, to $222.84 per share on January 29, 2025, a decline of about 24.49% in the span of just a single day.

Class Period

10/22/24 - 1/28/25

Deadline

April 28 2025

Learn More

33

Days Left

RKLB

Rocket Lab USA, Inc.

Deadline

April 28 2025

Class Period

11/12/24 - 2/25/25

Allegations

(1) the Company’s plans for three barge landing tests were significantly delayed; (2) a critical potable water problem was not scheduled to be fixed until January 2026, which delayed preparation of the launch pad; (3) as a result of the foregoing, there was a substantial risk that Rocket Lab’s Neutron rocket would not launch in mid-2025; (4) Neutron’s only contract was made at a discount with an unreliable partner; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/12/24 - 2/25/25

Deadline

April 28 2025

Learn More

40

Days Left

ELF

e.l.f. Beauty, Inc.

Deadline

May 5 2025

Class Period

11/1/23 - 11/19/24

Allegations

(i) contrary to its representations to investors, the Company was experiencing rising inventory levels as a consequence of flagging sales; (ii) Elf falsely attributed the rising inventory levels to, among other things, changes in its sourcing practices; (iii) to maintain investor confidence, Elf reported inflated revenue, profits, and inventory over several quarters; (iv) the Company’s business and/or financial prospects were overstated; (v) all of the foregoing, once revealed, would likely have a material negative impact on the Company; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

11/1/23 - 11/19/24

Deadline

May 5 2025

Learn More

40

Days Left

SWKS

Skyworks Solutions, Inc.

Deadline

May 5 2025

Class Period

7/30/24 - 2/5/25

Allegations

According to the complaint, defendants provided investors with material information concerning Skyworks’ expected revenue for the fiscal year 2025. Defendants’ statements included, among other things, confidence in Skyworks’ ability to expand its mobile business and capitalize on its growth potential by investing in new technologies to diversify its portfolio of offerings. On February 5, 2025, after market close, Skyworks announced its financial results for the first quarter of fiscal year 2025 and provided lower-than anticipated revenue guidance for the second quarter of fiscal year 2025. The Company attributed its results and low guidance to a “competitive landscape” that had “intensified” in recent years. Following this news, the price of Skyworks’ common stock declined dramatically. From a closing market price of $87.08 per share on February 5, 2025, Skyworks’ stock price fell to $65.60 per share on February 6, 2025, a decline of over 24% in the span of just a single day.

Class Period

7/30/24 - 2/5/25

Deadline

May 5 2025

Learn More

40

Days Left

APP

AppLovin Corporation

Deadline

May 5 2025

Class Period

5/10/23 - 2/25/25

Allegations

According to the complaint, defendants provided investors with material information concerning AppLovin’s financial growth and stability. Defendants’ statements included, among other things, confidence in AppLovin’s launch of its AXON 2.0 digital ad platform and using “cutting-edge AI technologies” to more efficiently match advertisements to mobile games, in addition to expanding into web-based marketing and e-commerce. Moreover, defendants publicly reported impressive financial results, outlooks, and guidance to investors, all while using dishonest advertising practices. The truth emerged on February 26, 2025, when analyst research reports emerged stating that AppLovin was reverse engineering and exploiting advertising data from Meta Platforms. The reports further alleged AppLovin was utilizing manipulative practices to artificially inflate their own ad click-through and app download rates, such as by having ads click on themselves or utilizing design gimmicks to trigger forced shadow downloads, erroneously inflating installation numbers and, in turn, its profit figures. Following this news, the price of AppLovin’s stock declined from $377.06 per share on February 25, 2025 to $331.00 per share on February 26, 2025.

Class Period

5/10/23 - 2/25/25

Deadline

May 5 2025

Learn More

40

Days Left

MRVI

Maravai LifeSciences Holdings, Inc.

Deadline

May 5 2025

Class Period

8/7/24 - 2/24/25

Allegations

(1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024; (3) its goodwill was overstated; and (4)as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

8/7/24 - 2/24/25

Deadline

May 5 2025

Learn More

40

Days Left

RC

Ready Capital Corporation

Deadline

May 5 2025

Class Period

11/7/24 - 3/2/25

Allegations

(1) significant non-performing loans in its CRE portfolio were not likely to be collectible; (2) Ready Capital would fully reserve these problem loans in order to “stabilize” its CRE portfolio; (3) this was not accurately reflected in Ready Capital’s current expected credit loss or valuation allowances; (4) as a result, the Company’s financial results would be adversely affected; and (5), as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/7/24 - 3/2/25

Deadline

May 5 2025

Learn More

44

Days Left

NEP

XPLR Infrastructure, LP

Deadline

May 9 2025

Class Period

1/26/21 - 1/27/25

Allegations

(i) XPLR was struggling to maintain its operations as a yieldco; (ii) defendants temporarily relieved this issue by entering into CEPF, convertible equity portfolio financing arrangements while downplaying the attendant risks; (iii) XPLR could not buy out CEPFs before their maturity date without risking significant unitholder dilution; (iv) as a result, defendants planned to halt cash distributions to investors and instead redirect those funds to, inter alia, buy out the Company’s CEPFs; (v) as a result of all the foregoing, XPLR’s yieldco business model and distribution growth rate was unsustainable; and (vi) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

1/26/21 - 1/27/25

Deadline

May 9 2025

Learn More

44

Days Left

DMRC

Digimarc Corporation

Deadline

May 9 2025

Class Period

5/2/24 - 2/26/25

Allegations

(1) a large commercial partner would not renew a large contract on the same terms; (2) as a result, Digimarc would renegotiate the large commercial contract; (3) as a result of the foregoing, the Company’s subscription revenue and annual recurring revenue would be adversely affected; (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/2/24 - 2/26/25

Deadline

May 9 2025

Learn More

47

Days Left

FLNC

Fluence Energy, Inc.

Deadline

May 12 2025

Class Period

11/29/23 - 2/10/25

Allegations

(1) Fluence’s relationship with its founders and largest sources of revenue, Siemens AG and The AES Corporation, was poised to decline; (2) Siemens Energy, Siemens AG’s U.S. affiliate, had accused the Company of engineering failures and fraud; (3) Fluence’s margins and revenue growth were inflated as Siemens and AES were moving to divest; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements related to Fluence’s battery energy storage business, as well as related financial results, growth, and prospects.

Class Period

11/29/23 - 2/10/25

Deadline

May 12 2025

Learn More

47

Days Left

GERN

Geron Corporation

Deadline

May 12 2025

Class Period

6/7/24 - 2/25/25

Allegations

According to the complaint, defendants provided investors with material information concerning defendants’ expectations for the launch and growth potential of Rytelo (imetelstat). Defendants’ statements included, among other things, confidence in Geron’s ability to capitalize on the purportedly significant unmet need for the drug and to execute on its commercial plan to target first-line ESA ineligible patients, while continually minimizing the risks associated with the burden of the weekly monitoring requirement for Rytelo and the impacts of seasonality and existing competition on the drug’s sales. On February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal 2024, disclosing that Rytelo’s growth had flattened over the preceding months. The Company attributed the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. Following this news, the price of Geron’s common stock declined dramatically. From a closing market price of $2.37 per share on February 25, 2025, Geron’s stock price fell to $1.61 per share on February 26, 2025, a decline of about 32.07% in the span of just a single day.

Class Period

6/7/24 - 2/25/25

Deadline

May 12 2025

Learn More

48

Days Left

TFII

TFI International Inc.

Deadline

May 13 2025

Class Period

4/26/24 - 2/19/25

Allegations

(1) the Company was losing small and medium business customers; (2) as a result, the Company’s TForce revenue was declining; (3) TFI was experiencing difficulties managing its costs; (4) as a result of the foregoing, the profitability of its largest business segment was declining; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

4/26/24 - 2/19/25

Deadline

May 13 2025

Learn More

48

Days Left

EU

enCore Energy Corp.

Deadline

May 13 2025

Class Period

3/28/24 - 3/2/25

Allegations

(1) enCore lacked effective internal controls over financial reporting; (2) enCore could not capitalize certain exploratory and development costs under GAAP; (3) as a result, its net losses had substantially increased; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

3/28/24 - 3/2/25

Deadline

May 13 2025

Learn More

54

Days Left

ZYXI

Zynex, Inc.

Deadline

May 19 2025

Class Period

3/13/23 - 3/11/25

Allegations

(1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, the Company inflated its revenue; (3) the Company’s practice of filing false claims drew scrutiny from insurers, including the U.S. military health insurance program, Tricare; (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

3/13/23 - 3/11/25

Deadline

May 19 2025

Learn More

55

Days Left

SANA

Sana Biotechnology, Inc.

Deadline

May 20 2025

Class Period

3/17/23 - 11/4/24

Allegations

(i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (iv) accordingly, defendants overstated Sana’s financial capacity to maintain its current operations and advance its existing product candidates; and (v) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

3/17/23 - 11/4/24

Deadline

May 20 2025

Learn More

55

Days Left

PPTA

Perpetua Resources Corp.

Deadline

May 20 2025

Class Period

4/17/24 - 2/13/25

Allegations

According to the complaint, defendants provided investors with material information concerning Perpetua’s expected initial capital expenditure for the Stibnite Gold Project. Defendants’ statements included, among other things, minimization of the impact of inflation and other potential sources for increased capital expenditure costs for the project. On February 13, 2025, Perpetua published an updated cash flow model for the Stibnite Gold Project, unveiling additional capital expenses of $952 million, a more than 75% increase from the original figures presented to investors and well beyond the suggested 10-20% increase contemplated by defendants. The Company attributed these increased costs on inflation, indirect costs, higher mining costs, and direct decisions defendants made with respect to the project, including the choice to change the design of the electrical poles from timber to steel and the decision to “buy-and-build instead of lease the oxygen plant.” Following this news, the price of Perpetua’s common stock declined dramatically. From a closing market price of $11.97 per share on February 13, 2025, Perpetua’s stock price fell to $9.29 per share on February 14, 2025, a decline of about 22.39% in the span of just a single day.

Class Period

4/17/24 - 2/13/25

Deadline

May 20 2025

Learn More

58

Days Left

UCTT

Ultra Clean Holdings, Inc.

Deadline

May 23 2025

Class Period

5/6/24 - 2/24/25

Allegations

According to the complaint, defendants provided investors with material information concerning the elevated demand from Chinese original equipment manufacturers (OEMs) and in the general Chinese domestic market for Ultra Clean’s products throughout the fiscal year 2024. Defendants’ statements included, among other things, reports of increased demand for the Company’s products and services in the domestic Chinese market and reports of increased revenue, including revenue doubling with no signs of slowing down, due to the elevated demand in China for Ultra Clean’s products and services. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the demand for Ultra Clean’s products and services in the domestic Chinese market; notably, that the Company was facing a customer ramp issue with one of its critical customers, as well as a combination of inventory and demand corrections, which, ultimately, caused weakness for Ultra Clean in China. On February 24, 2025, Ultra Clean published fourth quarter and full year 2024 fiscal results and hosted an associated earnings call, where the Company’s executives revealed that Ultra Clean was facing “demand softness” in China. In particular, Ultra Clean was facing decreased demand in China due to extended qualification timelines and inventory absorption. Investors and analysts reacted immediately to these revelations. The price of Ultra Clean’s common stock declined dramatically. From a closing market price of $36.06 per share on February 24, 2025, Ultra Clean’s stock price fell to $25.90 per share on February 25, 2025, a decline of over 28% in the span a single day.

Class Period

5/6/24 - 2/24/25

Deadline

May 23 2025

Learn More

Never Miss a Potential Recovery Again

Sign up for Class Action Alerts

$785,034,300 in Total Settlement Funds Available. See if you qualify!Find Out More

We Give Shareholders A Voice.

Settlements

Who We Are

Find an Attorney

Find a Case

Upcoming Deadlines

IAS

Integral Ad Science Holding Corp.

GO

Grocery Outlet Holding Corp.

MODV

ModivCare Inc.

Sign up for Class
Action Alerts